Table 2.
p values from the Spearman correlation of proteins measured by targeted mass spectrometry and clinical PD assessment scores in PD subjects and healthy controls (phase I)
| MMSE | Hoehn-Yahr | UPDRS I | UPDRS II | UPDRS III | UPDRS total score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MMSE | 4.0E-2 | (−0.23) | 3.0E-3 | (−0.31) | 5.3E-3 | (−0.29) | ||||||
| Hoehn-Yahr | 1.0E-13 | (−0.61) | 1.3E-42 | (−0.88) | 8.1E-19 | (−0.69) | 7.1E-26 | (−0.77) | ||||
| UPDRS I | 5.2E-14 | (−0.61) | 2.7E-19 | (−0.7) | 8.1E-7 | (−0.44) | 7.6E-13 | (−0.59) | ||||
| UPDRS II | 1.3E-42 | (−0.88) | 8.2E-19 | (−0.7) | 1.3E-15 | (−0.64) | 9.6E-27 | (−0.78) | ||||
| UPDRS III | 1.6E-2 | (−0.31) | 5.4E-19 | (−0.69) | 1.1E-6 | (−0.44) | 9.6E-16 | (−0.64) | 2.0E-77 | (−0.97) | ||
| UPDRS total score | 2.1E-2 | (−0.29) | 1.1E-25 | (−0.77) | 1.0E-12 | (−0.59) | 9.6E-27 | (−0.78) | 2.0E-77 | (−0.97) | ||
| A2M | 1.2E-2 | (−0.32) | 8.1E-7 | (−0.44) | 6.7E-5 | (−0.37) | ||||||
| ADIPOQ | 6.8E-5 | (−0.37) | 2.4E-2 | (−0.25) | 9.4E-6 | (−0.4) | 2.0E-4 | (−0.34) | 5.5E-5 | (−0.37) | ||
| C3 | 9.8E-3 | (−0.35) | 1.7E-3 | (−0.3) | 3.2E-3 | (−0.28) | 2.0E-4 | (−0.34) | 2.6E-4 | (−0.34) | ||
| CST3 | 2.6E-3 | (−0.28) | 5.0E-3 | (−0.26) | ||||||||
| DKK3 | 5.3E-4 | (−0.32) | 3.8E-2 | (−0.24) | 3.2E-5 | (−0.38) | 2.8E-5 | (−0.38) | 1.5E-5 | (−0.4) | ||
| FABP5 | 1.2E-2 | (−0.32) | 1.9E-2 | (−0.22) | 4.0E-2 | (−0.19) | ||||||
| GRN | 4.8E-7 | (−0.45) | 3.8E-7 | (−0.45) | 2.8E-8 | (−0.49) | 3.3E-8 | (−0.48) | ||||
| HPX | 4.6E-2 | (−0.25) | 5.3E-4 | (−0.32) | 2.2E-4 | (−0.34) | 2.1E-4 | (−0.34) | 9.2E-5 | (−0.36) | ||
| HSPA1L | 4.5E-2 | (−0.19) | 4.6E-2 | (−0.2) | 2.3E-3 | (−0.28) | 2.7E-3 | (−0.28) | ||||
| HSPA5 | 3.0E-2 | (−0.21) | 4.6E-2 | (−0.2) | 1.2E-3 | (−0.3) | 2.2E-3 | (−0.29) | ||||
| ITIH2 | 3.2E-2 | (−0.21) | ||||||||||
| MASP2 | 3.0E-2 | (−0.21) | 1.1E-2 | (−0.25) | 1.9E-2 | (−0.22) | 3.1E-2 | (−0.2) | ||||
| PGK1 | 5.6E-3 | (−0.25) | 1.0E-2 | (−0.24) | ||||||||
| PPP3CB | 3.4E-4 | (−0.34) | 3.1E-6 | (−0.42) | 2.6E-3 | (−0.28) | 5.3E-4 | (−0.32) | ||||
| PRG4 | 3.1E-2 | (−0.27) | ||||||||||
| PTGDS | 3.2E-2 | (−0.26) | 4.0E-2 | (−0.2) | 2.6E-3 | (−0.28) | 8.3E-3 | (−0.24) | ||||
| SELE | 1.3E-2 | (−0.24) | 4.7E-2 | (−0.23) | 1.3E-4 | (−0.35) | 1.4E-3 | (−0.3) | 5.1E-4 | (−0.32) | ||
| SERPINA3 | 3.2E-2 | (−0.26) | 3.8E-4 | (−0.33) | 7.9E-4 | (−0.31) | 1.5E-4 | (−0.35) | 1.4E-4 | (−0.35) | ||
| SERPINF2 | 3.1E-2 | (−0.27) | 3.4E-4 | (−0.34) | 3.8E-4 | (−0.33) | 1.2E-3 | (−0.3) | 1.1E-3 | (−0.3) | ||
| SERPING1 | 7.5E-03 | (−0.26) | 4.6E-02 | (−0.2) | 2.0E-3 | (−0.29) | 4.6E-3 | (−0.26) | ||||
| SPP2 | 3.0E-2 | (−0.21) | 3.7E-2 | (−0.19) | 4.7E-2 | (−0.19) | ||||||
| TUBA4A | 4.6E-2 | (−0.2) | 1.7E-2 | (−0.22) | 1.6E-2 | (−0.22) | ||||||
| VCAM1 | 8.0E-4 | (−0.31) | 3.0E-3 | (−0.28) | ||||||||
The correlation significance was determined by the Student’s two-tailed t-test. The p values were adjusted for multiple comparisons using the Benjamini–Hochberg procedure with alpha = 0.05. The p values are followed by correlation coefficients in parenthesis.
MMSE mini-mental state examination, UPDRS unified Parkinson’s disease rating scale.